- This event has passed.
BioForum – New Frontiers: Rethinking Antimicrobial Resistance
November 21, 2023 @ 12:00 pm - 2:30 pm AEDT
Event Navigation
About the event:
Join us for an important discussion during World Antimicrobial Awareness Week on the rise of drug-resistant infections. Explore this urgent threat to our health security and what can be done about it now and into the future.
Be informed about:
- Antimicrobial resistance – why it matters
- Rethinking treatments – alternative approaches
- Policy initiatives – supporting access, sustainability and R&D
- Strengthening the pipeline – protecting our ongoing health security.
What to expect:
- The latest updates from clinicians and industry experts
- Engaging information for diverse audiences
- Dynamic panel Q&A session
- In-person networking opportunities with peers.
Who should attend?
- Professionals seeking to improve knowledge and foster connections
- Policy makers and regulatory experts
- Clinicians, pharmacists and scientists engaging in antimicrobial resistance research, diagnostics, clinical practice and public health programs
- Patient advocates and not-for-profits
- Start-ups, entrepreneurs and investors.
Event details:
Date: Tuesday 21 November 2023
Time (AEDT):
11:45am: Guest arrival and registration
12:00pm: Networking lunch
1:00pm: Presentations and Q&A
2:30pm: Close
Format: Hybrid – in person and live-streamed
Venue: Davies Collison Cave, Level 15, Orica House, 1 Nicholson Street, Melbourne, VIC, 3000
Facilitator: Dr Patricia Vietheer, Senior Director, Strategy, Business Development & Planning, Biointelect
Speakers:
Richard Alm, Chief Scientific Officer, CARB-X
Renae Beardmore, Founder and Managing Director, Evohealth
Andrew Bowskill, Director of Stakeholder Engagement for Queensland, MTPConnect, Co-Chair, Australian AMR Network
Professor Trevor Lithgow, Director, Centre to Impact AMR, Monash University
Dr Phoebe Williams, Paediatrician and Paediatric ID Physician, Sydney Institute for Infectious Diseases
Host: BioMelbourne Network and Davies Collison Cave
Registration:
In-person: Members $85; Non Members $175
Online: Members $25; Non Members $45
This event is sponsored by the State Government of Victoria
Kindly hosted by Davies Collison Cave
Cancellation Policy
In-person registration:
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
Online registration:
Full refund given up to 3 days prior to the event
No refunds within 3 days of the event
Richard Alm, Chief Scientific Officer, CARB-X
Richard joined CARB-X following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company where he supported the progression of small molecule compounds from discovery through to late-stage clinical development and registration.
He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he had two post-doctoral positions in the AMR area, one in Australia and one in Canada.
He currently serves as the Chief Scientist at CARB-X, a global non-profit organisation that supports a diverse and innovative pipeline of traditional and non-traditional products to prevent, diagnose and treat infections caused by drug-resistant bacterial pathogens.
He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he had two post-doctoral positions in the AMR area, one in Australia and one in Canada.
He currently serves as the Chief Scientist at CARB-X, a global non-profit organisation that supports a diverse and innovative pipeline of traditional and non-traditional products to prevent, diagnose and treat infections caused by drug-resistant bacterial pathogens.
Renae Beardmore, Founder and Managing Director, Evohealth
Renae is an experienced advisor to the health sector. She has worked for thirty years in health, covering the spectrum of healthcare from policy development, regulation and reimbursement through to clinical delivery. Renae’s work is focused on ensuring that the system supports equitable patient access to care.
Renae is the founder and Managing Director of Evohealth. As the Pricing Advisor to the Pharmaceutical Benefits Pricing Authority (PBAC) Renae was responsible for the primary carriage of price negotiations for the Pharmaceutical Benefits Scheme (PBS). She has also held the role of Chief Pharmacist for the Australian Capital Territory (ACT) and was a member of the Australian Committee for Medicines Scheduling (ACMS) of the Therapeutic Goods Administration.
Renae is the previous National Vice-President of the Pharmaceutical Society of Australia and has been appointed by the Federal Minister for Health to Chair the Pharmaceutical Services Federal Committee of Inquiry since 2019.
Renae is the founder and Managing Director of Evohealth. As the Pricing Advisor to the Pharmaceutical Benefits Pricing Authority (PBAC) Renae was responsible for the primary carriage of price negotiations for the Pharmaceutical Benefits Scheme (PBS). She has also held the role of Chief Pharmacist for the Australian Capital Territory (ACT) and was a member of the Australian Committee for Medicines Scheduling (ACMS) of the Therapeutic Goods Administration.
Renae is the previous National Vice-President of the Pharmaceutical Society of Australia and has been appointed by the Federal Minister for Health to Chair the Pharmaceutical Services Federal Committee of Inquiry since 2019.
Andrew Bowskill, Director of Stakeholder Engagement for Queensland, MTPConnect, Co-Chair, Australian AMR Network
Andrew joined MTPConnect in 2019 and leads stakeholder engagement in Queensland. He also led the establishment of, and co-chairs MTPConnect’s catalytic body for Antimicrobial Resistance (AMR), the Australian AMR Network. Previously he was Manager of Industry and Regulatory Policy at Medicines Australia.
Andrew has a Bachelor of Pharmacy from the University of Otago, and extensive experience as a pharmacist in Australia and New Zealand.
Andrew has a Bachelor of Pharmacy from the University of Otago, and extensive experience as a pharmacist in Australia and New Zealand.
Professor Trevor Lithgow, Director, Centre to Impact AMR, Monash University
In 2009, Professor Trevor Lithgow was awarded an ARC Federation Fellowship to move to Monash University to apply new imaging technology and comparative genomics to understand the evolution of protein transport machines in bacteria. Professor Lithgow also led a mission funded by two cycles of NHMRC Program Grants, with collaborators at other institutes in Australia and the UK, to drive training for the next generation of research leaders in bacterial cell biology, bacteriophages and antimicrobial resistance (AMR) mechanisms.
In the period 2014-2019, he was awarded an ARC Laureate Fellowship to build capacity in cryo-electron microscopy, neutron reflectometry and super-resolution microscopy to address questions in bacterial cell biology using nanoscale imaging. In 2020, Lithgow established the Centre to Impact AMR at Monash and currently serves as Director.
Outside of science, Trevor spends most of his time with family but has also built a garden of indigenous plants on the Mornington Peninsula. Here, he divides his time between bird-watching, pulling out weeds and trying to avoid contracting Buruli ulcer.
In the period 2014-2019, he was awarded an ARC Laureate Fellowship to build capacity in cryo-electron microscopy, neutron reflectometry and super-resolution microscopy to address questions in bacterial cell biology using nanoscale imaging. In 2020, Lithgow established the Centre to Impact AMR at Monash and currently serves as Director.
Outside of science, Trevor spends most of his time with family but has also built a garden of indigenous plants on the Mornington Peninsula. Here, he divides his time between bird-watching, pulling out weeds and trying to avoid contracting Buruli ulcer.
Dr Phoebe Williams, Paediatrician and Paediatric ID Physician, Sydney Institute for Infectious Diseases
Phoebe is a paediatrician, infectious diseases physician and a senior lecturer within the School of Public Health, Faculty of Medicine, University of Sydney. She works as a clinician at The Sydney Children's Hospital Network and within the policy group of the National Centre for Immunisation and Research Surveillance [NCIRS], as part of the policy support team for ATAGI.
Phoebe completed her DPhil [PhD] as a Nuffield Department of Medicine scholar with the University of Oxford, undertaking a clinical trial for neonates with sepsis in rural Kenya, within the Oxford Tropical Medicine network in Kilifi, Kenya. Phoebe is an NHMRC Emerging Leader Fellow whose research is focused on antimicrobial resistance in children, particularly within resource-constrained settings in Southeast Asia. She is appointed as an advisor to the World Health Organization’s Paediatric Antibiotic Development Program (PADO) and Research Agenda into AMR on Human Health and leads a number of clinical trials in paediatric infectious diseases.
Phoebe completed her DPhil [PhD] as a Nuffield Department of Medicine scholar with the University of Oxford, undertaking a clinical trial for neonates with sepsis in rural Kenya, within the Oxford Tropical Medicine network in Kilifi, Kenya. Phoebe is an NHMRC Emerging Leader Fellow whose research is focused on antimicrobial resistance in children, particularly within resource-constrained settings in Southeast Asia. She is appointed as an advisor to the World Health Organization’s Paediatric Antibiotic Development Program (PADO) and Research Agenda into AMR on Human Health and leads a number of clinical trials in paediatric infectious diseases.
Related Events
